ATDBio has announced a strategic partnership with the Nucleic Acid Therapy Accelerator (NATA), a not-for-profit Medical Research Council (MRC) Unit operating at the intersection of academia, preclinical research, and industry. This collaboration will support NATA's mission to advance the development of nucleic acid therapies (NATs).

This collaboration brings together ATDBio's 20 years of expertise in complex oligonucleotide synthesis with NATA's position as a leading research accelerator in nucleic acid therapeutics. The partnership will enable NATA to leverage ATDBio's proven track record in synthesizing antisense oligonucleotides (ASOs) and small inhibitory RNA (siRNA), particularly for screening and preclinical studies.